

1 **Effectiveness of a mobile antiretroviral pharmacy and HIV care intervention on the**
2 **continuum of HIV care in rural Uganda**

3
4
5 **Francis Bajunirwe¹, Nicholas Ayebazibwe¹, Edgar Mulogo¹, Maria Eng², Janet**
6 **McGrath³, David Kaawa-Mafigiri³, Peter Mugenyi⁴, Ajay K. Sethi⁵**

7
8 Author affiliation:

- 9 1. Department of Community Health, Mbarara University of Science and Technology,
10 Uganda
11 2. Applied Science for Health, LLC, Baltimore, MD
12 3. Case Western Reserve University, Department of Anthropology
13 4. Joint Clinical Research Center
14 5. Department of Population Health Sciences, University of Wisconsin-Madison School of
15 Medicine and Public Health, USA.
16
17
18
19

20 **Author email addresses**

21 Francis Bajunirwe: fbaj@must.ac.ug,
22 Nicholas Ayebazibwe: nichoaken@gmail.com,
23 Edgar Mulogo: emulogo@must.ac.ug,
24 Maria Eng: meng@appscihealth.com,
25 Janet McGrath: janet.mcgrath@case.edu
26 David Kaawa-Mafigiri: dmk28@case.edu
27 Peter Mugenyi: pmugenyi@yahoo.co.uk ,
28 Ajay K. Sethi: ajay.sethi@wisc.edu
29

30
31 **Address correspondence to:**

32 Francis Bajunirwe, PhD, MBChB
33 Department of Community Health
34 Mbarara University of Science and Technology
35 P.O.BOX 1410, Mbarara, Uganda
36 Email: fbaj@must.ac.ug
37
38

40 **Abstract**

41 **Introduction:** Adherence to antiretroviral therapy (ART) is critical in order to achieve
42 viral suppression, one of three UNAIDS targets set for achievement before 2020. One of
43 the main barriers to adherence is the long distance between patient residences and
44 healthcare facilities. We designed an intervention, Mobile Antiretroviral Therapy and
45 HIV care (MAP-HC) in rural southwestern Uganda aimed to reduce travel distance and
46 hypothesized that MAP-HC would improve ART adherence and rates of viral load
47 suppression.

48 **Methods** The study was conducted at two sites, Kitagata and Itojo Hospitals, and these
49 are public health facilities located in rural southwestern Uganda. Patients who lived
50 >5km from the hospital were provided the option to participate. For each hospital, we
51 identified 4 health centres in the catchment area to serve as site for the mobile pharmacy.
52 Each site was visited once a month to provide ART refills, adherence counseling and
53 treatment of other illnesses. We measured patient waiting time, adherence and viral load
54 suppression before and after the intervention.

55
56 **Results:** We conducted baseline assessment among 292 patients at the two hospitals. The
57 mean waiting time at Kitagata Hospital changed from 4.48 hours before the intervention
58 but increased to 4.76 hours after the intervention ($p=0.13$). The proportion of patients
59 who missed an ART dose in the last 30 days dropped from 20% at baseline to 8.5% at 12
60 months after the intervention ($p=0.009$). The proportion of patients with detectable viral
61 load from 19.9% to 7.4% after the intervention ($p=0.001$).

62
63 **Conclusions:** Our study has showed that a mobile pharmacy intervention in rural Uganda
64 is feasible and resulted in improvement in adherence and viral load suppression.
65 Although it did not reduce patient waiting time at the clinic, we recommend a scale-up of
66 this intervention in rural areas where patients face challenges of transportation to the
67 clinic.

69 **Introduction**

70 Adherence to antiretroviral therapy (ART) is critical in order to achieve viral suppression
71 [1] or the third 90, one of three UNAIDS targets set for achievement before 2020. In
72 order to achieve viral load suppression, patients should take at least 95% of their
73 medications [2-4]. Although adherence levels in sub Saharan Africa are on average
74 higher than estimates in North America [5], patients in countries such as Uganda face
75 structural barriers to achieve high level adherence.

76
77 One of the main barriers to adherence is the long distance between one's place of
78 residence and healthcare facilities. [6, 7] Specifically, patients seeking HIV care and
79 treatment travel longer distances compared to their HIV negative counterparts. [8]
80 Several studies have examined geographical factors as barriers and systematic analysis
81 has shown that travel distance is a barrier across the continuum of HIV care from testing
82 to treatment and retention in care [9]. Patients narrate how they struggle to raise the
83 monthly transportation fee to the clinics to collect their medicines [10, 11]. Some patients
84 devised innovative ways such as pooling resources in order to secure their monthly pills,
85 with some patients making two-day arduous journeys to an HIV clinic. Long waiting
86 times because clinics are crowded [12] cause patients to view their monthly visits as
87 burdensome, competing with time needed to tend to gardens and other income generating
88 activities.

89
90 The World Health Organization now recommends the testing and initiation of ART for
91 all persons infected with HIV regardless of CD4 count or HIV stage [13], referred to the
92 "test and treat approach." Uganda, along with other HIV-affected countries across the
93 globe, is now implementing this strategy. The expected result is that HIV treatment
94 clinics will experience rising numbers of patients needing treatment, worsening crowding
95 and waiting times at these facilities. Such unintended effects of ART expansion are
96 barriers to maintaining HIV care continuation, leading to poor retention and or non-
97 adherence.

98
99 There is now a need for interventions that not only reduce distance to HIV treatment
100 clinics, but also have potential to decongest them. These may result in better adherence to
101 clinic visits, medications and improve viral load suppression. There is very limited
102 interventions of this nature that have been tested in resource-limited settings. The few
103 experiences with decentralized and community-based models in Africa have been
104 successful [14, 15] including more recently from Nigeria where a community-based
105 model increased adherence and retention in care [16]. More examples of such
106 interventions are needed in this era of "test and treat."

107
108 With funding from the Doris Duke Charitable Foundation's Operations Research on
109 AIDS Care and Treatment in Africa program, between 2009 and 2013, we developed and
110 operated an intervention, Mobile Antiretroviral Therapy and HIV care (MAP-HC) in
111 rural southwestern Uganda. Our intervention aimed to reduce travel distance and patient
112 cost associated with travel to collect medicines and, indirectly, reduce wait time and
113 crowding at the HIV clinic. We also hypothesized that MAP-HC would improve ART

114 adherence and rates of viral load suppression. We report the results of our program
115 evaluation.

116

117 **Methodology**

118

119 *Study setting*

120 The study was conducted at two sites, Kitagata and Itojo Hospitals, and these are public
121 health facilities located in rural southwestern Uganda. They were selected because they
122 were among the first district-level ART clinics serving a rural population. Kitagata
123 Hospital is located in Sheema District, Uganda, which is predominantly a rural
124 population of subsistence farmers. The area has a difficult terrain and transportation
125 around the district is mainly by motorcycle taxis or *boda bodas*. Itojo Hospital is located
126 just south in Ntungamo District with mixed subsistence farming and livestock as the
127 major sources of livelihood. At both hospitals, majority of patients travel several hours to
128 the hospital to receive their monthly ART refills. By the beginning of 2009, the
129 cumulative number of patients receiving ART was over 520 for Kitagata Hospital and
130 632 for Itojo Hospital.

131

132 *Development and Implementation of MAP-HC*

133

134 The implementation of the MAP-HC was done in three phases, the Preparation,
135 Identification, and Implementation phases. We engaged health workers and patients at
136 both ART clinics to ensure the process was participatory, but began the development of
137 MAP-HC at Kitagata Hospital where we had already established working relationships
138 with healthcare workers and hospital administration. Once MAP-HC was developed and
139 operational at Kitagata, we repeated our implementation steps at Itojo Hospital.

140

141 In the *preparation phase*, which began in March 2009 at Kitagata Hospital and October
142 2009 at Itojo Hospital, our team began to sensitize ART clients about the intervention.
143 We conducted a baseline survey at the hospital to measure patient demographics, place of
144 residence, distance travelled to the clinic, pre-intervention adherence to ART and viral
145 load suppression. We also defined the catchment area of the clinic and mapped patients'
146 places of residence by parish and village. We used this information to identify the
147 clusters or zones where majority of patients resided. The catchment area of residence was
148 then divided into 4 zones based on clustering of the patient population. Within each zone,
149 we identified a county- or sub-county- (Health Centre III) or parish-level (Health Centre
150 II) healthcare facilities, which was closer in distance than the district-level hospital
151 (Health Centre IV) to the majority of patients in that zone, to serve as a distribution point
152 to dispense antiretroviral therapy.

153

154 In the *identification phase*, clinicians at the hospital interacted with patients and informed
155 them about our proposed intervention. At Kitagata Hospital, where we first began to
156 work, patients were asked to choose whether they would wish to receive their refills at
157 our proposed ART dispensing sites or continue receiving their medications at the
158 hospital. Patients were enthusiastic for our proposed intervention, but expressed a desire
159 for healthcare services in addition to ART refills. We then worked with hospital

160 administration to determine the feasibility and logistics of adding healthcare delivery
161 elements to our intervention. Ultimately, we revised our intervention from being ART
162 dispensing alone (MAP) to one that also provides basic healthcare services (MAP-HC),
163 which is described further below.

164
165 Patients were offered MAP-HC services if they had been taking ART for at least 6
166 months, were considered stable on treatment by the physician, and lived further than five
167 kilometers from the district hospital, a distance determined by the Ministry of Health as
168 being excessive when traveling for one's healthcare. [17] In making their decision,
169 patients were asked to consider other issues such as privacy and whether the MAP-HC
170 site would be convenient to them.

171
172 In the *implementation phase*, we reviewed the appointment dates for all patients that
173 consented to participate in MAP-HC and synchronized appointment and ART refill dates
174 by zone. We obtained buy in from the district-level health service team, local government
175 and the healthcare facility where MAP-HC would be stationed. HIV care providers
176 selected a non-HIV clinic day during the week to operate MAP-HC and chose a day that
177 was also typically lighter at the hospital to allow the team be away.

178
179 *MAP-HC intervention*

180
181 The MAP-HC team consisted of five members: two nurses trained in dispensing ART
182 and monitoring adverse events, a trained medication dispenser, an ART adherence
183 counselor, a driver. The mobile team provided ART refills, adherence counseling, and
184 treatment of concomitant illnesses such as malaria, respiratory tract infections and other
185 conditions that did not require an admission. The physician who ordinarily runs the HIV
186 clinic was required to remain back at the hospital to serve other non-HIV care seeking
187 patients.

188 The MAP-HC team used the hospital's own vehicle and the research project investigators
189 provided reimbursement for fuel expenses and field day allowance at government
190 approved rates for health care staff. Patients received ART and basic care at MAP-HC
191 sites for three consecutive visits, but were required to return to the district hospital for the
192 fourth visit in order to be seen by the physician.

193
194 *Data collection*

195 We compared measurements before and after the MAP. First, we conducted a baseline
196 assessment at the two district hospitals to measure baseline features such as waiting time,
197 adherence and viral load. Next, we implemented the project, and then collected post
198 intervention measurements. We measured waiting time at the hospitals and sampled
199 patients for viral load and adherence measurement at the MAP sites. We repeated
200 measurements of patient waiting time, adherence and viral load 12 months after the MAP
201 was implemented.

202
203 *Study outcomes*

204 The primary outcome for this evaluation was viral load suppression. The secondary
205 outcomes were attendance at MAP sites, adherence to antiretroviral medication, and

206 waiting time at the hospital. We hypothesized that adherence and viral load suppression
207 would improve among patients attending MAP and that MAP would decongest the ART
208 clinic at the hospital resulting in reduced waiting time.

209

210 To measure patient waiting time at the hospital, we positioned 4 research assistants at the
211 ART Clinic following the order of flow at the clinic. The research assistants were
212 positioned at the entrance/registration area, adherence officer room, clinician consultation
213 rooms, and dispensary. Patients followed this natural order and collected their
214 medications at the dispensary before departure. On arrival at the entrance of the ART
215 clinic, the research assistant wrote the arrival time on a small script of paper, which they
216 handed to the patient. The research assistant at the next station wrote the time when the
217 patient completed the visit at each station, and the final research assistant at the
218 dispensary wrote the time and collected the script from the patient before their departure.
219 The typical layout for the clinic at Kitagata Hospital is shown in Figure 1 below.

220

221 ----- Insert Figure 1 here -----

222

223 The circled numbers in Figure 1 represent the positions where the research assistants
224 were positioned to collect the waiting time data.

225

226 Adherence was measured using self-report. Blood samples were drawn from the patients
227 and sent to a regional testing laboratory in Mbarara for viral load testing. VL were
228 measured using Amplicor system® from Roche. Results were relayed back to the health
229 care providers 4 weeks after sample collection.

230

231 Sampling, sample size and data analysis

232 We used consecutive sampling to collect baseline data. We aimed to interview 300 study
233 participants at baseline to determine the proportion of participants that were living
234 outside of 5km from the hospital. At the follow up for evaluation, we did not calculate
235 sample size. The number was determined by the resources available to conduct viral load
236 testing, as this was the primary outcome for the evaluation.

237 We summarized the baseline characteristics using 5km as the cut off. This is because the
238 Ministry of Health recommends that persons should reside within a radius of 5km from a
239 health facility [18]. We compared continuous baseline variables using non-parametric
240 tests and categorical outcomes using Chi square tests. We compared the pre- and post-
241 intervention proportions of patients who were adherence or had viral load suppression
242 using Chi square test and a t-test to compare waiting time. Paired tests were not used
243 since the sampling process did not necessarily include the same patients before and after
244 the intervention.

245

246 Human subjects' issues

247 The proposal was approved by the Research Ethics Committee at Mbarara University of
248 Science and Technology and by the Uganda National Council of Science and
249 Technology. Study procedures were explained to the clients at the HIV clinic. Individual
250 written informed consent was obtained and all study participants signed a consent form
251 once they understood study procedures and accepted to participate. Participants were

252 made aware they were free to decline participation in the MAP but continue to receive
 253 their medications at the hospital. Confidentiality was maintained by using number
 254 identifications for the patients on study materials and questionnaires.

255

256 **Results**

257 We conducted baseline assessment interviews among 292 patients at both Kitagata and
 258 Itojo Hospital. Almost two thirds were women, with a median age of 37 years. Majority
 259 lived more than 5km away from the hospital and the results are shown in Table 1. As
 260 expected, those who lived nearer were more likely to walk compared to those who lived
 261 further. Participants who lived further than 5 km also had significantly lowed median
 262 monthly incomes compared to those who lived near the health facility (p=0.021). Those
 263 who lived further than 5km also spent more time and money in travel to the hospital.

264

265 -----Insert Table 1 here -----

266

267 Table 1: Baseline characteristics of rural patients attending ART clinic at Kitagata and
 268 Itojo Hospital, south western Uganda, 2009

269

Characteristic	Overall n=292	Less than 5km n=79	More than 5km n=213	p value
Gender				
Male	104 (36%)	39 (49%)	65 (31%)	0.003
Female	188 (64%)	40 (51%)	148 (69%)	
Age (median, IQR)	37 (32, 43)	36 (32, 42)	38 (33, 44)	0.041
Has job income	183 (63%)	54 (68%)	129 (61%)	0.221
Monthly income USD (median, IQR)	15 (10, 50)	25 (12.5, 62)	15 (10, 45)	0.021
Transport to clinic:				
Walking	91 (31%)	44 (56%)	47 (22%)	<0.001
Rode a bicycle	20 (7%)	6 (8%)	14 (7%)	
Took a bodaboda	88 (30%)	24 (30%)	64 (30%)	
Took a minibus	93 (32%)	5 (6%)	88 (41%)	
Travel time to clinic (minutes median, IQR)	90 (60, 140)	60 (30, 90)	120 (100, 150)	<0.001
Travel cost USD (median, IQR)	2.5 (1.5, 3.0)	1.5 (1.0, 2.0)	3.0 (2.0, 4.0)	<0.001

270

271

272

273

274 Participants had comparable 3 and 30 day self-report adherence regardless of whether
 275 they lived within or outside 5km from the hospital (p=0.577) and these results are shown
 276 in Table 2 below. However, participants who lived further than 5km were more likely to
 277 report having ever missed a pill compared to those who lived near (p=0.013). The

278 participants that lived further than 5km were also more likely to report distance as a
 279 barrier to their travel to the clinic.

280

281 -----Insert Table 2 here -----

282 Table 2: Characteristics related to antiretroviral treatment among rural patients at
 283 Kitagata Hospital, southwestern Uganda

Characteristic	Overall n=292	Less than 5km n=79	More than 5km n=213	p value
Months on ART (median, IQR)	25 (14, 36)	29 (14, 39)	24 (14, 36)	0.57
Missed appointment	47 (16%)	9 (11%)	38 (18%)	0.134
Distance affects coming to clinic:				
All of the time	64 (22%)	5 (6%)	59 (28%)	<0.001
Most of the time	44 (15%)	6 (8%)	38 (18%)	
Rarely	112 (38%)	29 (37%)	83 (39%)	
Never	72 (25%)	39 (49%)	33 (15%)	
Missed ART dose:				
In last 3 days	4 (1%)	0 (0%)	4 (2%)	0.577
In last 30 days	57 (20%)	16 (20%)	41 (19%)	0.847
Missed an entire day of ART in last 30 days	35 (12%)	8 (10%)	27 (13%)	0.551
Ever missed ART dose	123 (42%)	24 (30%)	99 (45%)	0.013

284

285

286

287

288 Post intervention results

289 Figure 2 shows a bar graph with attendance at the MAP, with numbers of participants
 290 expected at each month visit versus those who actually turned up. The graph shows that
 291 consistently, the attendance was nearly 100% and in some instances, exceeded the
 292 expected numbers.

293

294 The mean waiting time at the hospital was 4.48 hours before the intervention and
 295 increased to 4.76 hours after the intervention, however this change was not statistically
 296 significant (p=0.13) and these results are shown in Table 3. The proportion of patients
 297 who missed an ART dose in the last 30 days dropped from 20% at baseline to 8.5% at 12
 298 months after the intervention and this drop was statistically significant (p=0.009).
 299 Similarly, the proportion of patients with detectable viral load significantly dropped from
 300 19.9% to 7.4% after the intervention (p=0.001).

301

302 -----Insert Table 3 here -----

303 Table 3: Changes in the treatment outcomes before and after implementation of the
 304 Mobile antiretroviral therapy program, southwestern Uganda
 305

Characteristic	Before intervention March 2009	After intervention March 2010	p value
Waiting time (in hours) at the main hospital (mean, standard deviation)	4.48 (1.7)	4.76 (1.7)	0.13
Proportion of patients who missed ART dose in the last 30 days	57/292 (19.5%)	9/106 (8.5%)	<0.009
Proportion of patients with detectable viral load	58/292 (19.8%)	9/122 (7.4%)	0.001

306
 307
 308
 309
 310

311 Discussion

312
 313
 314
 315
 316
 317
 318

In this mobile pharmacy intervention for ART in rural western Uganda, there was significant reduction in the proportion of patients who missed an ART dose in the last 30 days and a significant decrease in the proportion of patients with detectable viral load. However, the intervention had no impact on the waiting time at the district hospital.

319
 320
 321
 322
 323
 324
 325
 326
 327
 328

Our intervention targeted participants that lived more than 5km from the hospital and our data indicate this was the right target population. Not only did they take more time to travel to the hospital, they also paid more to reach the facility and reported more difficulty trying to reach it. Yet, these participants who lived further away were more likely to earn less per month compared to those who lived nearer, placing more burden on their meager resources to meet their transportation fee to the hospital per month. Those who lived further than 5km were more likely to reside in more rural remote establishments. Although majority of the districts are predominantly rural, the hospital was located in a semi-urban setting. This more rural population needed the intervention.

329
 330
 331
 332
 333
 334
 335
 336
 337
 338

The hospital ART clinics were overcrowded pre-intervention. We hypothesized that MAP would decongest them by taking away a large proportion who needed refills. Despite the intervention, there was no significant decrease in waiting time at the hospital. On closer scrutiny, the lack of decrease in waiting time came as no surprise because the overall ART clinic population for instance at Kitagata grew from 500 patients to almost 1000 patients within a year following the implementation of the MAP. The potential impact of the intervention was washed away by the exponential growth in the clinic size. This is an important challenge to anticipate as clinic populations are expected to grow even more as Uganda is now implementing the ‘test and treat’ approach to achieve 90-90-90 UNAIDS targets. As efforts to identify and treat more people grow, the burden on

339 health centers grows, and without other approaches to providing treatment, the increased
340 burden could eventually stall or reverse gains made.

341

342 Our results agree with other studies in sub Saharan Africa and elsewhere where results
343 show that programs to get patients to receive treatment at lower level health facilities are
344 successful [19] or even have better treatment outcomes compared to those at higher level
345 facilities [20, 21]. Our study did not perform a direct comparison between higher and
346 lower level facilities but instead compared a pre-intervention (district hospital) versus a
347 post-intervention (lower level facility) outcome outcomes. In our evaluation, the better
348 outcomes following the MAP intervention may be attributed to the elimination of
349 distance, a structural barrier to adherence. The results agree with our hypothesis that
350 removal of distance barrier would result in improvement in adherence and viral load
351 suppression. In the United States and other resource rich countries, a related kind of
352 intervention designed to improve adherence and involved the referral of patients who
353 were stable on ART to HIV-focused community pharmacies [22, 23] also showed
354 significant success.

355

356 Our results and others elsewhere, suggest that ART programs should consider scale up of
357 ART to proximal health facilities or community pharmacies in rural areas and where
358 patients have to travel long distances and or difficult terrain such as that here in rural
359 western Uganda where our study was based. However, there may be concerns about the
360 long term sustainability of this kind of program, especially where additional financial
361 support is required as was the case in our program. To ensure sustainability, the mobile
362 pharmacies should embrace the concept of decentralization of HIV services and based on
363 a recent review [24] should be considered for integration with other well-known
364 successful interventions such as short messaging services, adherence clubs and peer
365 counseling, or even merge with other outreach programs such as vaccinations.

366

367 Our evaluation has important strengths. First, the evaluation was conducted in a rural
368 population. This is important because majority of populations in sub Saharan Africa and
369 Uganda live in rural areas but also because patients in rural areas are more likely to
370 experience distance as a barrier to health care seeking. Second, we measured several
371 markers of impact of the MAP including crowding, adherence and viral load suppression.
372 Although self-reported adherence may be influenced by social desirability bias, viral load
373 suppression is insulated from subjective reporting.

374

375 Our study has some limitations. In our sampling, some of the patients involved in the pre-
376 intervention assessment were not necessarily involved in the post intervention VL and
377 adherence measurement. In the post-intervention assessment, we randomly sampled MAP
378 patients for viral load measurement, regardless of whether they had been involved in the
379 baseline assessment or not. Although this sampling approach partly engages components
380 of convenience in the sampling, it is unlikely to have influenced the results because all
381 patients receiving care at a MAP site lived more than 5 km from the hospital and reported
382 distance as a barrier to adherence. The sampling approach is consistent with other
383 pseudo-experimental study designs that involve a pre- and post-evaluation comparison.

384 Lastly, we did not conduct a cost-effectiveness analysis for this intervention and future
385 evaluations should incorporate data collection to support this analysis.

386

387

388 In conclusion, our study has showed that a mobile pharmacy intervention in rural Uganda
389 is feasible and resulted in improvement in adherence and viral load suppression.

390 Although it did not reduce patient waiting time at the clinic, we recommend a scale-up of
391 this intervention in rural areas where patients face challenges of transportation to the
392 clinic.

393

394

395 **Acknowledgements**

396 We would like to thank the staff and administration of Kitagata and Itojo Hospitals in
397 western Uganda for supporting our research team in the recruitment and data collection
398 process. We thank the Bushenyi district local government for supporting the
399 implementation of the mobile ART program, and last but not least the patients who
400 participated in the implementation and evaluation of the program. This work was funded
401 by Operations Research on AIDS Care and Treatment in Africa (ORACTA) Award
402 (2007012) from the Doris Duke Charitable Foundation.

403

404

406 **References**


407

- 408 1. Gross R, Bilker WB, Friedman HM, Strom BL. Effect of adherence to newly
409 initiated antiretroviral therapy on plasma viral load. *AIDS* (London, England).
410 2001;15(16):2109-17. Epub 2001/10/31. PubMed PMID: 11684930.
- 411 2. Bangsberg DR, Hecht FM, Charlebois ED, Zolopa AR, Holodniy M, Sheiner L, et
412 al. Adherence to protease inhibitors, HIV-1 viral load, and development of drug
413 resistance in an indigent population. *AIDS* (London, England). 2000;14(4):357-66. Epub
414 2000/04/19. PubMed PMID: 10770537.
- 415 3. Arnsten JH, Demas PA, Grant RW, Gourevitch MN, Farzadegan H, Howard AA,
416 et al. Impact of active drug use on antiretroviral therapy adherence and viral suppression
417 in HIV-infected drug users. *Journal of general internal medicine*. 2002;17(5):377-81.
418 Epub 2002/06/06. PubMed PMID: 12047736; PubMed Central PMCID:
419 PMCPMC1495042.
- 420 4. Sethi AK, Celentano DD, Gange SJ, Moore RD, Gallant JE. Association between
421 adherence to antiretroviral therapy and human immunodeficiency virus drug resistance.
422 *Clinical infectious diseases : an official publication of the Infectious Diseases Society of*
423 *America*. 2003;37(8):1112-8. Epub 2003/10/03. doi: 10.1086/378301. PubMed PMID:
424 14523777.
- 425 5. Mills EJ, Nachega JB, Buchan I, Orbinski J, Attaran A, Singh S, et al. Adherence
426 to antiretroviral therapy in sub-Saharan Africa and North America: a meta-analysis.
427 *Jama*. 2006;296(6):679-90. Epub 2006/08/10. doi: 10.1001/jama.296.6.679. PubMed
428 PMID: 16896111.
- 429 6. Shubber Z, Mills EJ, Nachega JB, Vreeman R, Freitas M, Bock P, et al. Patient-
430 Reported Barriers to Adherence to Antiretroviral Therapy: A Systematic Review and
431 Meta-Analysis. *PLoS medicine*. 2016;13(11):e1002183. Epub 2016/11/30. doi:
432 10.1371/journal.pmed.1002183. PubMed PMID: 27898679; PubMed Central PMCID:
433 PMCPMC5127502.
- 434 7. Bajunirwe F, Arts EJ, Tisch DJ, King CH, Debanne SM, Sethi AK. Adherence
435 and treatment response among HIV-1-infected adults receiving antiretroviral therapy in a
436 rural government hospital in Southwestern Uganda. *Journal of the International*
437 *Association of Physicians in AIDS Care* (Chicago, Ill : 2002). 2009;8(2):139-47. Epub
438 2009/03/05. doi: 10.1177/1545109709332470. PubMed PMID: 19258526.
- 439 8. Akullian AN, Mukose A, Levine GA, Babigumira JB. People living with HIV
440 travel farther to access healthcare: a population-based geographic analysis from rural
441 Uganda. *Journal of the International AIDS Society*. 2016;19(1):20171. Epub 2016/02/13.
442 doi: 10.7448/ias.19.1.20171. PubMed PMID: 26869359; PubMed Central PMCID:
443 PMCPMC4751409.
- 444 9. Lankowski AJ, Siedner MJ, Bangsberg DR, Tsai AC. Impact of geographic and
445 transportation-related barriers on HIV outcomes in sub-Saharan Africa: a systematic
446 review. *AIDS and behavior*. 2014;18(7):1199-223. Epub 2014/02/25. doi:
447 10.1007/s10461-014-0729-8. PubMed PMID: 24563115; PubMed Central PMCID:
448 PMCPMC4047127.
- 449 10. Tuller DM, Bangsberg DR, Senkungu J, Ware NC, Emenyonu N, Weiser SD.
450 Transportation costs impede sustained adherence and access to HAART in a clinic
451 population in southwestern Uganda: a qualitative study. *AIDS and behavior*.

- 452 2010;14(4):778-84. Epub 2009/03/14. doi: 10.1007/s10461-009-9533-2. PubMed PMID:
453 19283464; PubMed Central PMCID: PMCPMC2888948.
- 454 11. Biadgilign S, Deribew A, Amberbir A, Deribe K. Barriers and facilitators to
455 antiretroviral medication adherence among HIV-infected paediatric patients in Ethiopia:
456 A qualitative study. SAHARA J : journal of Social Aspects of HIV/AIDS Research
457 Alliance. 2009;6(4):148-54. Epub 2010/05/21. PubMed PMID: 20485854.
- 458 12. Hardon AP, Akurut D, Comoro C, Ekezie C, Irunde HF, Gerrits T, et al. Hunger,
459 waiting time and transport costs: time to confront challenges to ART adherence in Africa.
460 AIDS care. 2007;19(5):658-65. Epub 2007/05/17. doi: 10.1080/09540120701244943.
461 PubMed PMID: 17505927.
- 462 13. Consolidated guidelines on the use of antiretroviral drugs for treating and
463 preventing HIV infection
464 Recommendations for a public health approach - Second edition 2016 [March 30, 2018].
465 <http://www.who.int/hiv/pub/arv/arv-2016/en/>].
- 466 14. Bemelmans M, van den Akker T, Ford N, Philips M, Zachariah R, Harries A, et
467 al. Providing universal access to antiretroviral therapy in Thyolo, Malawi through task
468 shifting and decentralization of HIV/AIDS care. Tropical medicine & international health
469 : TM & IH. 2010;15(12):1413-20. Epub 2010/10/21. doi: 10.1111/j.1365-
470 3156.2010.02649.x. PubMed PMID: 20958897.
- 471 15. Bedelu M, Ford N, Hilderbrand K, Reuter H. Implementing antiretroviral therapy
472 in rural communities: the Lusikisiki model of decentralized HIV/AIDS care. The Journal
473 of infectious diseases. 2007;196 Suppl 3:S464-8. Epub 2008/01/10. doi: 10.1086/521114.
474 PubMed PMID: 18181695.
- 475 16. Avong YK, Aliyu GG, Jatau B, Gurmnaan R, Danat N, Kayode GA, et al.
476 Integrating community pharmacy into community based anti-retroviral therapy program:
477 A pilot implementation in Abuja, Nigeria. PLoS One. 2018;13(1):e0190286. Epub
478 2018/01/11. doi: 10.1371/journal.pone.0190286. PubMed PMID: 29320531; PubMed
479 Central PMCID: PMCPMC5761864.
- 480 17. Guidelines for Designation, Establishment and Upgrading of Health Facilities in
481 Uganda; <http://health.go.ug/docs/guidelines.pdf> Accessed December 10, 2018. 2011.
- 482 18. HEALTH SECTOR DEVELOPMENT PLAN 2015/16 - 2019/20: Ministry of
483 Health, Uganda. Available from:
484 http://health.go.ug/sites/default/files/Health%20Sector%20Development%20Plan%202015-16_2019-20.pdf
485
- 486 19. Grimsrud A, Sharp J, Kalombo C, Bekker LG, Myer L. Implementation of
487 community-based adherence clubs for stable antiretroviral therapy patients in Cape
488 Town, South Africa. Journal of the International AIDS Society. 2015;18:19984. Epub
489 2015/05/30. doi: 10.7448/ias.18.1.19984. PubMed PMID: 26022654; PubMed Central
490 PMCID: PMCPMC4444752.
- 491 20. Fatti G, Grimwood A, Bock P. Better antiretroviral therapy outcomes at primary
492 healthcare facilities: an evaluation of three tiers of ART services in four South African
493 provinces. PLoS One. 2010;5(9):e12888. Epub 2010/09/30. doi:
494 10.1371/journal.pone.0012888. PubMed PMID: 20877631; PubMed Central PMCID:
495 PMCPMC2943483.
- 496 21. Grimsrud A, Lesosky M, Kalombo C, Bekker LG, Myer L. Implementation and
497 Operational Research: Community-Based Adherence Clubs for the Management of

498 Stable Antiretroviral Therapy Patients in Cape Town, South Africa: A Cohort Study.
499 Journal of acquired immune deficiency syndromes (1999). 2016;71(1):e16-23. Epub
500 2015/10/17. doi: 10.1097/qai.0000000000000863. PubMed PMID: 26473798.
501 22. Cocohoba JM, Murphy P, Pietrandoni G, Guglielmo BJ. Improved antiretroviral
502 refill adherence in HIV-focused community pharmacies. Journal of the American
503 Pharmacists Association : JAPhA. 2012;52(5):e67-73. Epub 2012/10/02. doi:
504 10.1331/JAPhA.2012.11112. PubMed PMID: 23023860; PubMed Central PMCID:
505 PMCPMC4607273.
506 23. Hirsch JD, Rosenquist A, Best BM, Miller TA, Gilmer TP. Evaluation of the first
507 year of a pilot program in community pharmacy: HIV/AIDS medication therapy
508 management for Medi-Cal beneficiaries. Journal of managed care pharmacy : JMCP.
509 2009;15(1):32-41. Epub 2009/01/08. doi: 10.18553/jmcp.2009.15.1.32. PubMed PMID:
510 19125548.
511 24. Haberer JE, Sabin L, Amico KR, Orrell C, Galarraga O, Tsai AC, et al. Improving
512 antiretroviral therapy adherence in resource-limited settings at scale: a discussion of
513 interventions and recommendations. Journal of the International AIDS Society.
514 2017;20(1):21371. Epub 2017/06/21. doi: 10.7448/ias.20.1.21371. PubMed PMID:
515 28630651; PubMed Central PMCID: PMCPMC5467606.
516


Figure 1: Lay out for the ART clinic at Kitagata Hospital and location of research assistants to measure patient waiting time



bioRxiv preprint doi: <https://doi.org/10.1101/2020.03.26.010101>; this version posted March 26, 2020. The copyright holder for this preprint (which was not peer-reviewed) is the author/funder. It is made available under a [CC-BY 4.0 International license](https://creativecommons.org/licenses/by/4.0/).

The circled numbers indicate the position of the research assistants who were tracking patient waiting time.

Figure 2: Number of patients attending at the Mobile Antiretroviral therapy program, southwestern Uganda, January – December 2010



bioRxiv preprint doi: <https://doi.org/10.1101/538930>; this version posted October 10, 2019. The copyright holder for this preprint (which was not peer-reviewed) is the author/funder. It is made available under aCC-BY 4.0 International license.